SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Total Voting Rights

28 Dec 2012 07:00

RNS Number : 8922T
Silence Therapeutics PLC
28 December 2012
 



 

 

Silence Therapeutics plc ("Silence" or the "Company")

TVR

 

In accordance with the Financial Services Authority's Disclosure and Transparency Rules, the Company hereby announces that it has 1,871,552,737 ordinary shares of 0.1p each ("Ordinary Shares") in issue, with each Ordinary Share carrying the right to one vote. The Company does not hold any Ordinary Shares in Treasury.

 

The above figure of 1,871,552,737 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Services Authority's Disclosure and Transparency Rules.

 

 

 

Silence Therapeutics

Tim Freeborn (+44 20 7491 6520)

Email: t.freeborn@silence-therapeutics.com

 

N+1 Singer

Shaun Dobson/Jennifer Wyllie

+44 20 7496 3000

shaun.dobson@n1singer.com

jenny.wyllie@n1singer.com

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVREAEANFAFAFFF
Date   Source Headline
26th May 20053:40 pmPRNFinal Results
3rd May 20052:13 pmPRNMerger Update
24th Feb 200511:03 amPRNHolding(s) in Company
9th Feb 20051:48 pmPRNHolding(s) in Company
9th Feb 20051:45 pmPRNHolding(s) in Company
7th Feb 20052:43 pmPRNEGM Statement
21st Jan 200510:06 amPRNNotice of EGM
12th Jan 20052:25 pmPRNHolding(s) in Company
6th Jan 200510:13 amPRNHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.